Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585068 | 0.85 | SIRT6 (0.41) | BCHEPDK2GPR119 | |
| SCHEMBL2594780 | 0.84 | PDK2 (0.46) | BCHEPDK2GPR119 | |
| SCHEMBL9933040 | 0.83 | BCHE (0.40) | BCHENOTUMPDK2GPR119 | |
| SCHEMBL27908969 | 0.79 | BCHE (0.49) | BCHEGPR119 | |
| SCHEMBL21196734 | 0.77 | BCHE (0.41) | BCHEPDK2GPR119 | |
| SCHEMBL13386133 | 0.74 | BCHE (0.40) | LGMNBCHEGPR119 | |
| SCHEMBL19747099 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL13386210 | 0.73 | BCHE (0.42) | LGMNBCHEGPR119 | |
| SCHEMBL21196800 | 0.73 | CDK9 (0.39) | — | |
| SCHEMBL2594032 | 0.72 | PDK2 (0.36) | BCHEPDK2GPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | LGMN 612/4885BCHE 1570/4885NOTUM 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.